The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

E.B. Kornilova

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

K.I. Polyakova

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

T.V. Shkurko

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Pirogov Russian National Medical Research University, Ministry of Health of Russia, Moscow, Russia

O.V. Kniazev

GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy

A.D. Ermolaeva

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Loginov Moscow Clinical Scientific and Practical Center of the Moscow Healthcare Department, Moscow, Russia ,Sechenov First Moscow State Medical University Ministry of Health of Russia, Moscow, Russia

M.V. Davydovskaya

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

T.N. Ermolaeva

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

A.G. Fisun

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow

Authors:

E.B. Kornilova, K.I. Polyakova, T.V. Shkurko, O.V. Kniazev, A.D. Ermolaeva, M.V. Davydovskaya, T.N. Ermolaeva, A.G. Fisun

More about the authors

Views: 3680

Downloaded: 75

To cite this article:

Kornilova EB, Polyakova KI, Shkurko TV, Kniazev OV, Ermolaeva AD, Davydovskaya MV, Ermolaeva TN, Fisun AG. Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):55‑70. (In Russ.)
https://doi.org/10.17116/dokgastro2019803155

Recommended articles:
Postoperative pain asse­ssment in patients with Crohn’s disease. Russian Journal of Evidence-Based Gastroenterology. 2023;(1):37-41
Extraintestinal mani­festations of inflammatory bowel disease. Russian Journal of Evidence-Based Gastroenterology. 2023;(1):93-98
Early Ileocecal Rese­ction for Crohn’s Disease. Russian Journal of Evidence-Based Gastroenterology. 2023;(3):10-17
Real-world effe­ctiveness of uste­kinumab in maintenance therapy for Crohn´s disease. Russian Journal of Evidence-Based Gastroenterology. 2023;(3):29-42
The role of nutrition in the prevention and treatment of inflammatory bowel disease. Russian Journal of Preventive Medi­cine. 2023;(3):123-129

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.